Aarti Drugs Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/yzjcs8weaarn5w92ogug1jc6.pdf

Key Takeaways


Revenue & Volume Dynamics

Adhish Patil: "As far as pricing environment of API is concerned, we saw decline in December quarter. Then from December to March quarter, the prices have almost stabilized now, so they are not falling further."

Margin Trajectory

Adhish Patil: "So considering that negative rate variance, we would target to reach like 10% top line growth. We will target that in spite of negative rate variance. And as far as EBITDA is concerned, so we are now more and more confident that we should be crossing the 14% mark at the company level. And slowly, if the situation continues to be stable, then probably we'll try to reach the 15% mark."

Capacity & Capex

Adhish Patil: "apart from metformin product, there has not been any capacity increase because most of those top 15 molecules are mature molecules."

Oncology Pipeline


Regulatory & Plant Status


Guidance & Commitments

CommitmentSpecificsTimeline
Top-line growth10% growth despite ~5-8% negative rate varianceFY25
EBITDA marginCross 14%; aim for 15% if situation remains stableFY25
Sayakha greenfield commencementProject to commence operationsEnd of Q1 FY25
Sayakha scale-upRamp to full scaleQ4 FY25
Tarapur dermatology ramp-upRamp-up throughout H1H1 FY25
Oncology revenue contributionINR300-350 crores from 12-14 products24-36 months
Formulation revenueDouble from current ~INR300 croresNext 3 years
Overall revenue targetINR4,000-4,500 crores5-6 years
Steady-state EBITDA margin15.5-16% at INR4,000 crores turnoverAt scale
Volume growth target~15% volume growthComing years
FY25 capexINR200-250 croresFY25
FY26 onward capexINR150-200 crores (plus potential oncology/API capex)FY26 onward
Baddi plant FDA clearanceOptimistic of getting clearanceAt the earliest

Key Metrics

MetricQ4 FY24
Consolidated revenue₹621 cr, decline of 16.4% YoY
Standalone revenue₹560.64 cr, decline of 19.6% YoY, of which 13.6% was negative rate variance
EBITDA₹87 cr, margin at 14.0%, improved 130 bps YoY
PAT₹47 cr, margin at 7.6%
Formulation segment revenue₹68 cr for the quarter; full year ₹325 cr, growth of 18.5% YoY
Standalone domestic revenue share67% of standalone revenue
Standalone export revenue share35% of standalone revenue
API volume growth (Q4 YoY)-6% overall; domestic flat with -1%, export -15%
API volume growth (full year FY24)7% overall; domestic 16% to 17%
Net cash flow from operations₹359 cr as of March 31, 2024, versus ₹133 cr as of March 31, 2023
Capex incurred (FY24)₹226 cr
Total debt (consolidated)₹563 cr; short-term ₹215 cr, long-term ₹348 cr
Debt-to-equity ratio0.44x consolidated, 0.4x standalone
Return on capital employed (FY24)14.2%
Return on equity (FY24)13.9%
Capacity utilization (excl. greenfield)75% to 79%
FY25 revenue growth target10% top line growth, despite ~5% to 8% negative rate variance
FY25 EBITDA margin targetcrossing 14%, aiming for 15% if conditions remain stable
Oncology pipeline ANDAs filed (U.S.)1 filed so far, 12 to 14 molecules in pipeline over next 6 to 18 months